Loading…
Develops antibody therapies for chronic urticaria (hives), mast cell disorders and cancer.
Develops antibody therapies for chronic urticaria (hives), mast cell disorders and cancer.
Has no product sales; trial costs are paid from money raised from investors. Barzolvolimab is in late-stage trials for chronic hives and related skin disorders, so the next steps are trial results and, if approved, building a sales force or finding a partner to sell it.
Moat: none (IP / patents). Clinical-stage biotech with a differentiated mast-cell-targeting antibody but no approved products yet.
Headquarters: Hampton, New Jersey, US · Founded: 1983 · Employees: 198
Size Celldex Therapeutics (CLDX) is a United States Health Care company (Biotechnology) with a market value of $2.35B, the 1698th largest of 3,117 United States companies the cockpit tracks. Shares closed at $29.87 on 6 Nov 2026.
Performance Over six months the shares fell 12.1%, against +8.1% for the median peer and -1.1% for the United States market (cap-weighted) — 6th lowest of 20 in its peer set.
Growth Revenue fell 97.3% over the last twelve months (peer median +0.3%); the operating margin is -206,220.2% (peer median -13.6%).
Valuation It trades at 10,375.3× enterprise value to sales against a peer median of 15.6× (most expensive of 14).
Next results Next results expected around 11 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $158,000 | $1.54M | $7.02M | $6.88M | $2.36M |
| Revenue growth | — | -78% | +2% | +192% | — |
| Gross profit | -$3.24M | -$1.83M | $3.84M | $3.88M | $957,000 |
| EBITDA | -$322M | -$284M | -$192M | -$139M | -$106M |
| Net income | -$301M | -$259M | -$158M | -$141M | -$112M |
| Free cash flow | -$242M | -$214M | -$160M | -$109M | -$106M |
| Capital expenditure | $6.54M | $2.71M | $1.92M | $1.82M | $1.83M |
| Total debt | $4.90M | $2.34M | $3.81M | $2.54M | $4.03M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Celldex Therapeutics CLDX | $2.35B | -12% | -97% | -206,220% | 10,375.3× | n/a |
| Amgen AMGN | $249B | +40% | +9% | 36% | 7.4× | 1.8% |
| Cogent Biosciences COGT | $5.49B | -9% | n/a | n/a | n/a | n/a |
| Novartis NOVN.SW | $298B | +15% | -4% | 30% | 6.3× | 1.7% |
| Sanofi SAN.PA | $113B | +14% | +15% | 27% | 2.6× | -5.4% |
| Roche RO.SW | $385B | +22% | -1% | 31% | 5.6× | 0.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | CLDX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +1.9% | -0.8% | 8th highest of 21 |
| 6-month return | -12.1% | +8.1% | 6th lowest of 20 |
| Distance from 52-week high | -33.8% | -28.6% | 9th lowest of 21 |
| Revenue growth (TTM) | -97.3% | +0.3% | 3rd lowest of 16 |
| Operating margin | -206,220.2% | -13.6% | lowest of 14 |
| EV / Sales | 10,375.3× | 15.6× | most expensive of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Celldex Therapeutics CLDX | United States | $2.35B | -12% | -97% | -206,220% | 10,375.3× | n/a | n/a |
| Zealand Pharma A/S ZEAL.CO | Denmark | $2.32B | -32% | -49% | 51% | 0.3× | n/a | n/a |
| BGI Genomics 300676.SZ | China | $2.39B | -4% | 0% | -14% | 3.7× | n/a | n/a |
| Hemab Therapeutics COAG | United States | $2.29B | +95% | n/a | n/a | n/a | n/a | n/a |
| Septerna SEPN | United States | $2.28B | +105% | +13,520% | -57% | 19.5× | 18.7% | n/a |
| Pharvaris PHVS | United States | $2.41B | +14% | n/a | n/a | n/a | n/a | n/a |
| Vimian VIMIAN.ST | Sweden | $2.26B | +41% | +8% | 19% | 4.9× | 12.5% | +44.5% |
| Sinocelltech 688520.SS | China | $2.25B | -23% | -40% | -75% | 15.6× | n/a | n/a |
| MBX Biosciences MBX | United States | $2.47B | +25% | n/a | n/a | n/a | n/a | n/a |
| SKBS 302440.KS | South Korea | $2.22B | -11% | +23% | -25% | 4.5× | n/a | n/a |
| Immunome IMNM | United States | $2.21B | -17% | -100% | n/a | n/a | n/a | n/a |
| Aurinia Pharmaceuticals AUPH | United States | $2.21B | +8% | +21% | 45% | 5.5× | 5.1% | +41.4% |
| Recursion Pharmaceuticals RXRX | United States | $2.19B | +6% | +56% | -725% | 25.1× | n/a | n/a |
| Lakefront Biotherapeutics LKFT.AS | Netherlands | $2.19B | +25% | +259% | 60% | n/a | n/a | n/a |
| Palvella Therapeutics PVLA | United States | $2.53B | +45% | -100% | n/a | n/a | n/a | n/a |
| Vera Therapeutics VERA | United States | $2.15B | -18% | n/a | n/a | n/a | n/a | n/a |
| Evopoint Biosciences 688837.SS | China | $2.58B | n/a | n/a | n/a | 67.9× | n/a | n/a |
| Arcus Biosciences RCUS | United States | $2.59B | -28% | -55% | -415% | 17.1× | n/a | n/a |
| Hitgen 688222.SS | China | $2.12B | +23% | +42% | 27% | 19.1× | 38.7% | +16.8% |
| Shenzhen Kangtai Biological Products 300601.SZ | China | $2.11B | -9% | -9% | 6% | 5.6× | 25.3% | +3.4% |
| Xencor XNCR | United States | $2.66B | +178% | -29% | -206% | 22.6× | n/a | n/a |